Drugs /
ipatasertib
Back to Drugs List
Associated Genetic Biomarkers
Overview
Clinical Trials
Ipatasertib has been investigated in 31 clinical trials, of which 25 are open and 6 are closed. Of the trials investigating ipatasertib, 5 are phase 1 (4 open), 9 are phase 1/phase 2 (8 open), 13 are phase 2 (9 open), and 4 are phase 3 (4 open).
HER2 Negative, HER2 Deficient Expression, and ER Negative are the most frequent biomarker inclusion criteria for ipatasertib clinical trials.
Breast carcinoma, malignant solid tumor, and prostate adenocarcinoma are the most common diseases being investigated in ipatasertib clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.